Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
IP

NASDAQ · IPHA

Innate Pharma S.A.

Healthcare · Biotechnology

$2.26

Up+$0.17 (+8.13%)

Updated Aug 23, 2026, 3:28 PM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
159.21M
P/E ratio
-3.1
Dividend yield
0.00%
52-week range
$1.17 – $2.71
Volume
44.36K
Avg. volume
194.86K

Price performance

IPHA price history

1M range · 0 trading sessions · Daily adjusted prices

IPHA does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IPHA news

The latest Smart Investors Daily articles mentioning IPHA.

Stock researchCompany · Overview

IPHA research

Overview

Company profile and research snapshot.

Company profile

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.50
Implied upside
—
Analysts
9
IPHA recent ratings
DateFirmRatingTarget
Jun 22, 2026ODDO BHFBuy—
May 14, 2026H.C. WAINWRIGHT & CO., LLCBuy—
Apr 6, 2026PORTZAMPARC BNP PARIBASBuy—
Jan 26, 2026PORTZAMPARC BNP PARIBASBuy—
Jan 19, 2026PORTZAMPARC BNP PARIBASBuy—
Open full forecast

News briefing

No generated briefing is available yet.

businesswire.com · Dec 11, 2025

Innate Pharma Releases Its 2026 Financial Calendar

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication of revenue and cash position for 1Q2026 May 21, 2026: Annual General Shareholders Meeting September 17, 2026: Publication of half year financial statements November 5, 2026: Publication of revenue and cash position for 3Q2026 All financia.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By